Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261


Masoud Tavazoie
Masoud Tavazoie, M.D., Ph.D.
Chief Executive Officer & Co-founder

Masoud is co-founder, Board Director, and the Chief Executive Officer of Rgenix.

David Darst
David Darst, M.B.A.

David co-leads Rgenix’s financing, corporate development, and drug development efforts.

Robert Wasserman, M.D.
Chief Medical Officer

Bob oversees clinical development of Rgenix’s first-in-class programs.

Isabel Kurth
Isabel Kurth, Ph.D.
VP of Research

Isabel leads Rgenix’s research and target discovery efforts.

Stephen Wald, MS
Stephen Wald
VP of Chemistry & Pharmaceutical Sciences

Steve is responsible for chemical, analytical and formulation development, and manufacturing scale-up, of Rgenix’s drug candidates.

Foster Gonsalves
Foster Gonsalves, Ph.D., M.P.H.
VP of Drug Development & Strategy

Foster currently heads translational development of Rgenix’s pipeline and leads the implementation of the biomarker and diagnostic strategy. He is also a key member of the corporate strategy team.

Corey Sohmer
Corey Sohmer, M.B.A.
VP of Finance & Accounting

Corey brings to Rgenix more than 25 years of progressive leadership experience in finance and accounting.

Michael Szarek
Michael Szarek, Ph.D.
VP of Clinical & Regulatory Affairs

Michael leads clinical and regulatory affairs at Rgenix.

Anne Assmus, Ph.D.
Head of Business Development
Anne heads business development at RGENIX, where she focuses on strategic partnerships for the target discovery platform, preclinical and clinical stage programs.